Last reviewed 2026-04-23 · How we verify

Recombinant Hepatitis B Virus Vaccine

This vaccine stimulates an immune response against the hepatitis B virus.

This vaccine stimulates an immune response against the hepatitis B virus. Used for Prevention of hepatitis B infection.

At a glance

Mechanism of action

By introducing a recombinant form of the hepatitis B virus surface antigen, the vaccine triggers the body's immune system to produce antibodies against the virus, providing protection against infection.

Approved indications

• Prevention of hepatitis B infection

Common side effects

• Injection site pain
• Fatigue
• Headache

Key clinical trials

• Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
• Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
• Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (PHASE3)
• Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults (PHASE2)
• Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults (PHASE1, PHASE2)
• TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B (PHASE1)
• Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B (PHASE1)
• A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Recombinant Hepatitis B Virus Vaccine CI brief — competitive landscape report
• Recombinant Hepatitis B Virus Vaccine updates RSS · CI watch RSS
• Universidad de Valparaiso portfolio CI